Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Correction to: Nature Cancer https://doi.org/10.1038/s43018-026-01163-w, published online 12 May 2026. In the version of the article initially published, in the top-left graph of Fig. 3b, the y-axis label was “CD4+CD69+ (%, delta)” but should have been “CD8+CD69+ (%, delta)”. In the top-right box of Fig. 5d, the label “Post-GNOS-PV01” should have read “Pre-GNOS-PV01”. These corrections have been made to the HTML and PDF versions of the article.
Abstract Glioblastoma is a fatal disease with a median prognosis of 12–18 months. Recent studies have shown encouraging results using neoantigen-based vaccines to stimulate glioblastoma-directed immune responses, but overall immunogenicity has been low.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
